Press release
Synovial Sarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Synovial Sarcoma Research. Learn more about our innovative pipeline today! @ Synovial Sarcoma Pipeline Outlook [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Synovial Sarcoma Pipeline Report
* In June 2025, Adaptimmune announced a study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
* In June 2025, Epizyme Inc . conducted a study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body.
* DelveInsight's Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
* The leading Synovial Sarcoma Companies such as Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
* Promising Synovial Sarcoma Pipeline Therapies such as TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.
Stay informed about the cutting-edge advancements in Synovial Sarcoma treatments. Download for updates and be a part of the revolution in oncology care @ Synovial Sarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Synovial Sarcoma Emerging Drugs Profile
* AL3818: Advenchen Laboratories
Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor and , c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.
* Tazemetostat: Ipsen
Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process. Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of "relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)" in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.
* DS-2243a: Daiichi Sankyo
DS-2243a is an investigational bispecific T-cell engager (BiTE) developed by Daiichi Sankyo, currently being studied for the treatment of advanced synovial sarcoma. This agent is designed to target tumors that express the HLA-A2 molecule and the cancer-testis antigen NY-ESO, both of which are commonly found in synovial sarcoma cells. By binding to both the tumor antigen and cytotoxic T lymphocytes, DS-2243a aims to direct the patient's immune system specifically against synovial sarcoma cells, potentially improving the body's ability to recognize and kill these cancerous cells. The ongoing Phase I clinical trial is focused on evaluating the safety, tolerability, and initial signs of efficacy of DS-2243a in patients with advanced synovial sarcoma who have limited treatment options.
The Synovial Sarcoma Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
* Synovial Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.
Learn more about Synovial Sarcoma Drugs opportunities in our groundbreaking Synovial Sarcoma research and development projects @ Synovial Sarcoma Unmet Needs [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Synovial Sarcoma Companies
Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Synovial Sarcoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Synovial Sarcoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Synovial Sarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Synovial Sarcoma Pipeline Report
* Coverage- Global
* Synovial Sarcoma Companies- Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
* Synovial Sarcoma Pipeline Therapies- TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.
* Synovial Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Synovial Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Synovial Sarcoma Pipeline on our website @ Synovial Sarcoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Synovial Sarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Synovial Sarcoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AL3818: Advenchen Laboratories
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tazemetostat: Ipsen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* DS-2243a: Daiichi Sankyo
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Synovial Sarcoma Key Companies
* Synovial Sarcoma Key Products
* Synovial Sarcoma- Unmet Needs
* Synovial Sarcoma- Market Drivers and Barriers
* Synovial Sarcoma- Future Perspectives and Conclusion
* Synovial Sarcoma Analyst Views
* Synovial Sarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=synovial-sarcoma-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synovial Sarcoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4098456 • Views: …
More Releases from ABNewswire
The Neighbourhood The Wourld Tour 2026: Cheapest Tickets Available Now - Apply C …
The Neighbourhood's The Wourld Tour 2026 brings the alt-rock band's signature sound to arenas worldwide, supporting their new album (((((ultraSOUND))))). Kicking off March 28 in Austin, TX (Moody Center), the tour hits North America, Europe, Australia, Asia, and more through October 2026-including stops at Madison Square Garden (NYC), TD Garden (Boston), Kia Forum (LA), and recent additions like Little Caesars Arena (Detroit, Nov 19).
The Neighbourhood's The Wourld Tour 2026 [https://www.capitalcitytickets.com/The-Neighbourhood-Tickets]…
Andatel Grande Patong Phuket: 40-50M THB Mold Remediation After 6-Year Coastal C …
Andatel Grande Patong Phuket addresses extensive mold damage from unprecedented six-year COVID closure (March 2023-March 2026) through comprehensive remediation program. The 122-room property invested 40-50 million Thai Baht (35% of total 120-140M budget) demolishing and rebuilding affected ceilings and walls. Coastal humidity exceeding 80% without air conditioning created severe mold penetration throughout property.
PATONG, Phuket, Thailand - February 22, 2026 - One of the best Andatel Grande Patong Phuket option in…
Best Deals on MercyMe 2026 Tour Tickets: Get Affordable Seats at CapitalCityTick …
MercyMe's Wonder + Awe Tour 2026 kicks off March 12 in Greensboro, NC, featuring hits like "I Can Only Imagine" and new tracks from their upcoming album. With special guests Big Daddy Weave, Tim Timmons, and Sam Wesley, the 24+ city spring run spans the U.S., from East Coast arenas to West Coast venues, wrapping April 25 in Spokane, WA.
MercyMe's Wonder + Awe Tour 2026 [https://www.capitalcitytickets.com/MercyMe-Tickets] is bringing an uplifting…
Upcoming Book Offers Readers a Rare Perspective, Taking Them on a Mother's Journ …
Sarah Standifird's upcoming book, Citizen's Prey, will be released on March 28 and offers a rare, unflinching look at what happens when families are forced to navigate the justice system after preventable tragedy.
With years of experience in the legal industry, Sarah Standifird once worked alongside attorneys nationwide. Now, she writes from the other side of the courtroom-as a grieving mother navigating the system as a client-offering a rare and unflinching…
More Releases for Synovial
Synovial Sarcoma Market Projected to Reach USD 420 Million by 2034
Synovial sarcoma (SS) is a rare and aggressive form of soft tissue sarcoma, most commonly affecting adolescents and young adults. Though it accounts for only 5-10% of all soft tissue sarcomas, its rarity and severity make it a significant focus of rare cancer research. The disease is characterized by its chromosomal translocation (t(X;18)) and its tendency to metastasize, primarily to the lungs, creating challenges in long-term patient survival.
Download Full PDF…
Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an…
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Synovial…
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development.
Synovial Sarcoma: Introduction
Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to…
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,…
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size…
